Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 4/20 | 0.40 |
| ▸ | ABCC8 | Q09428 | 4/20 | 0.40 |
| ▸ | KCNJ11 | Q14654 | 4/20 | 0.40 |
| ▸ | KCNJ8 | Q15842 | 4/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.35 |
| ▸ | AR | P10275 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | VEGFA | P15692 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15606450 | 0.77 | ABCC9 (0.44) | ABCC9ABCC8KCNJ11KCNJ8SLC22A12 | |
| SCHEMBL15545458 | 0.75 | ALDH1A1 (0.53) | ABCC9ABCC8KCNJ11KCNJ8AR | |
| SCHEMBL15606505 | 0.71 | ABCC9 (0.43) | ABCC9ABCC8KCNJ11KCNJ8AR | |
| SCHEMBL15544689 | 0.68 | ALDH1A1 (0.44) | — | |
| SCHEMBL15545328 | 0.67 | ALDH1A1 (0.41) | SLC22A12PGRVEGFAEPAS1 | |
| SCHEMBL17213719 | 0.64 | EPAS1 (0.36) | ABCC9ABCC8KCNJ11KCNJ8SLC22A12 | |
| SCHEMBL15555781 | 0.64 | JAK2 (0.46) | — | |
| SCHEMBL30192879 | 0.63 | ALDH1A1 (0.53) | ABCC9ABCC8KCNJ11KCNJ8SLC22A12 | |
| SCHEMBL16555420 | 0.63 | ALDH1A1 (0.53) | ABCC9ABCC8KCNJ11KCNJ8SLC22A12 | |
| SCHEMBL15545106 | 0.62 | RAD51 (0.43) | PGRVEGFAEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2870143-B1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-29 | — | — | US | disclosed |
| EP-2870143-A1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | F. Hoffmann-La Roche AG (CH) | 2015-05-13 | — | — | EP | disclosed |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2014-01-09 | — | — | US | disclosed |
| WO-2014006066-A1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | ABCC9 1009/4885ABCC8 1178/4885KCNJ11 2678/4885 |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | ABCC9 1009/4885ABCC8 1178/4885KCNJ11 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.